News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Researchers Receive Grants From National Comprehensive Cancer Network Oncology Research Program Funded Through GlaxoSmithKline (GSK)


9/6/2012 9:58:59 AM

FORT WASHINGTON, Pa.--(BUSINESS WIRE)--The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) recently awarded 11 research grants to investigators following a review of proposals submitted in response to the NCCN Dabrafenib and Trametinib Request for Proposals. These grants were made possible through a $4-million research grant from GlaxoSmithKline to scientifically evaluate the clinical effectiveness of dabrafenib (GSK2118436) and trametinib (GSK1120212) in treatment of advanced melanoma and other cancers.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES